Adjuvant anti-PD-1 therapy in high-risk cutaneous squamous-cell carcinoma: post hoc insights from the C-POST and KEYNOTE-630 studies

Background: Cutaneous squamous-cell carcinoma (cSCC) is cured with surgery with or without radiotherapy in most cases, but patients with high-risk features remain prone to recurrence. Until recently, no systemic adjuvant therapy was available. Recently, two phase III trials assessed post-operative a...

Descrición completa

Detalles Bibliográficos

Principais autores:	S. Cavalieri, A. Ottini, C. Bergamini, S. Alfieri, I. Nuzzolese, E. Colombo, B. Lombardi Stocchetti, L. Licitra
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2026-03-01
Series:	Immuno-Oncology and Technology
Assuntos:	squamous-cell carcinoma adjuvant immunotherapy cemiplimab pembrolizumab
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2590018825005179
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!